Quote:

---

Saw nothing but funneling money back into their private company, since they will use their patients which would put us shareholders at expense.

---

If they are talking about current patients that would be a bad idea. Those patients might have to take a drug break from their current treatment of a month before they could be enrolled. On top of which as their symptoms started returning during the break there's a good chance they'd restart on their current regimen. But the worst part is those in the placebo arm would almost definitely return to maraviroc and statins completely wrecking the trial results.